Degeneration of spared axons following partial white matter lesion: implications for optic nerve neuropathies
- PMID: 9743562
- DOI: 10.1006/exnr.1998.6811
Degeneration of spared axons following partial white matter lesion: implications for optic nerve neuropathies
Abstract
Neuroprotective therapy is a relatively new development in the approach to the treatment of acute and chronic brain damage. Though initially viewed in the framework of acute CNS injuries, the concept was recently extended to include chronic injuries, in which at any given time there are some neurons in an acute phase of degeneration coexisting with others that are healthy, marginally damaged, or dead. The healthy neurons and those that are only marginally damaged are the potential targets for neuroprotection. For the development of neuroprotective therapies, it is essential to employ an animal model in which the damage resulting from secondary degeneration can be quantitatively distinguished from primary degeneration. This is of particular relevance when the site of the damage is in the white matter (nerve fibers) rather than in the gray matter (cell bodies). In the present work we reexamine the concepts of secondary degeneration and neuroprotection in white matter lesions. Using a partial crush injury of the adult rat optic nerve as a model, we were able to assess both primary and secondary nerve damage. We show that neurons whose axons were not damaged or only marginally damaged after an acute insult will eventually degenerate as a consequence of their existence in the degenerative environment produced by the injury. This secondary degeneration does not occur in all of the neurons at once, but affects them in a stepwise fashion related to the severity of the damage inflicted. These findings, which may be applicable to the progression of acute or chronic neuropathy, imply that neuroprotective therapy may have a beneficial effect even if there is a time lag between injury and treatment.
Copyright 1998 Academic Press.
Similar articles
-
Alpha2-adrenoreceptor agonists are neuroprotective in a rat model of optic nerve degeneration.Invest Ophthalmol Vis Sci. 1999 Jan;40(1):65-73. Invest Ophthalmol Vis Sci. 1999. PMID: 9888428
-
NMDA-receptor antagonist protects neurons from secondary degeneration after partial optic nerve crush.J Neurotrauma. 1997 Sep;14(9):665-75. doi: 10.1089/neu.1997.14.665. J Neurotrauma. 1997. PMID: 9337128
-
Secondary degeneration of the optic nerve following partial transection: the benefits of lomerizine.Exp Neurol. 2009 Mar;216(1):219-30. doi: 10.1016/j.expneurol.2008.11.026. Epub 2008 Dec 11. Exp Neurol. 2009. PMID: 19118550
-
Optic nerve and neuroprotection strategies.Eye (Lond). 2004 Nov;18(11):1075-84. doi: 10.1038/sj.eye.6701588. Eye (Lond). 2004. PMID: 15534592 Review.
-
Dendritic and synaptic protection: is it enough to save the retinal ganglion cell body and axon?J Neuroophthalmol. 2008 Jun;28(2):144-54. doi: 10.1097/WNO.0b013e318177edf0. J Neuroophthalmol. 2008. PMID: 18562848 Review.
Cited by
-
The retina as a window to the brain-from eye research to CNS disorders.Nat Rev Neurol. 2013 Jan;9(1):44-53. doi: 10.1038/nrneurol.2012.227. Epub 2012 Nov 20. Nat Rev Neurol. 2013. PMID: 23165340 Review.
-
T cell immunity to copolymer 1 confers neuroprotection on the damaged optic nerve: possible therapy for optic neuropathies.Proc Natl Acad Sci U S A. 2000 Jun 20;97(13):7446-51. doi: 10.1073/pnas.97.13.7446. Proc Natl Acad Sci U S A. 2000. PMID: 10861010 Free PMC article.
-
Apolipoprotein E gene ε4ε4 is associated with elevated risk of primary open angle glaucoma in Asians: a meta-analysis.BMC Med Genet. 2014 May 19;15:60. doi: 10.1186/1471-2350-15-60. BMC Med Genet. 2014. PMID: 24885013 Free PMC article.
-
Role of microglia/macrophage polarisation in intraocular diseases (Review).Int J Mol Med. 2024 May;53(5):45. doi: 10.3892/ijmm.2024.5369. Epub 2024 Mar 29. Int J Mol Med. 2024. PMID: 38551157 Free PMC article. Review.
-
Harnessing the immune system for neuroprotection: therapeutic vaccines for acute and chronic neurodegenerative disorders.Cell Mol Neurobiol. 2001 Dec;21(6):617-27. doi: 10.1023/a:1015139718466. Cell Mol Neurobiol. 2001. PMID: 12043837 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical